Answers are grounded in this paper and cite their sources.
Anti-ageing research is moving at a fast pace and in multiple directions, but the single biggest change that has occurred in the last decade is a shift in its objective from lifespan to healthspan. Meaningless and painful extra few years are useless, but modest longevity with good health, free from disease and disability, is now the new goal. New research is bridging molecular biotechnology and aesthetic surgery platforms and the paradigm of anti-ageing medicine has pivoted from superficial aesthetics to targeted cellular rejuvenation, creating a crucial intersection with regenerative plastic surgery. The breakthrough domains include epigenetic reprogramming, senolytics, metabolic modulation and artificial intelligence. The research on rapamycin, an immunosuppressant, metformin, an oral hypoglycaemic and Glucagon-like peptide-1 (GLP-1) drug for weight loss and nicotinamide adenine dinucleotide boosters to study their anti-ageing effect is progressing at different stages. Senolytics that kill the senescent cells or zombie cells of the ageing body are being studied in early human trials to ascertain their safety and efficacy. Cellular reprogramming by four Yamanaka factors is the newest avenue of research in geroscience, where ageing cells are reset partially just enough to wipe away the ‘epigenetic marks’ of ageing without erasing a cell’s identity.
No takes yet. Share an insight, caveat, or question.
Surajit Bhattacharya (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: